Sutenamo contains Sunitinib, an oral multikinase inhibitor used primarily for the treatment of advanced renal cell carcinoma (RCC), gastrointestinal stromal tumors (GISTs), and pancreatic neuroendocrine tumors (PNETs). Sunitinib works by inhibiting tumor growth and angiogenesis, helping to slow cancer progression.

Mechanism of Action

• Sunitinib inhibits multiple tyrosine kinases, including:

  • VEGFR-1, VEGFR-2, VEGFR-3 (angiogenesis inhibition)

  • PDGFR-α, PDGFR-β (tumor proliferation inhibition)

  • c-KIT (affecting GIST tumor growth)

• By blocking these pathways, it reduces tumor vascularization and prevents cancer cell proliferation.

  Uses

  • Treatment of advanced or metastatic renal cell carcinoma (RCC).

  • Treatment of gastrointestinal stromal tumors (GISTs) not responsive to imatinib.

  • Treatment of pancreatic neuroendocrine tumors (PNETs).

  • Helps slow tumor progression and improve survival in advanced cancers.

    Adverse Effects

    • Fatigue, weakness

    • Nausea, vomiting, diarrhea

    • Hand-foot syndrome (redness, pain, or peeling of palms/soles)

    • High blood pressure (hypertension)